Published in Clin Biochem Rev on August 01, 2006
Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int (2009) 1.37
The assessment of fracture risk. J Bone Joint Surg Am (2010) 1.27
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract (2009) 1.06
Low bone mineral density in men with chronic obstructive pulmonary disease. Respir Res (2011) 0.96
Bone turnover in nutrition-related disorders. Wien Med Wochenschr (2007) 0.93
Polymorphisms in the inflammatory genes CIITA, CLEC16A and IFNG influence BMD, bone loss and fracture in elderly women. PLoS One (2012) 0.87
Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. Osteoporos Int (2012) 0.86
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Osteoporos Int (2014) 0.85
Polymorphisms in the macrophage migration inhibitory factor gene and bone loss in postmenopausal women. Bone (2010) 0.83
Nanoparticles of cobalt-substituted hydroxyapatite in regeneration of mandibular osteoporotic bones. J Mater Sci Mater Med (2012) 0.83
The role of biochemical markers of bone turnover in osteoporosis management in clinical practice. Clin Biochem Rev (2006) 0.80
Greater Skeletal Gains in Ovary Intact Rats at Maturity Are Achieved by Supplementing a Standardized Extract of Butea monosperma Stem Bark that Confers Better Bone Conserving Effect following Ovariectomy and Concurrent Treatment Withdrawal. Evid Based Complement Alternat Med (2013) 0.78
Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz. BMC Res Notes (2012) 0.77
Heterogeneity of biological bone markers in idiopathic male osteoporosis. Rheumatol Int (2011) 0.76
Association of Blood Biomarkers of Bone Turnover in HIV-1 Infected Individuals Receiving Anti-Retroviral Therapy (ART). J AIDS Clin Res (2015) 0.75
Bone health status in Indian women. Indian J Med Res (2013) 0.75
Germinated Pigmented Rice (Oryza Sativa L. cv. Superhongmi) Improves Glucose and Bone Metabolisms in Ovariectomized Rats. Nutrients (2016) 0.75
Effects of Administration of Amlodipine and Lacidipine on Inflammation-Induced Bone Loss in the Ovariectomized Rat. Inflammation (2016) 0.75
A biochemical approach for assessing cutoffs at the age thresholds of 14 and 18 years: a pilot study on the applicability of bone specific alkaline phosphatase on an Italian sample. Int J Legal Med (2016) 0.75
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med (1990) 3.76
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res (2002) 3.15
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (2002) 3.10
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
Prediction of rapid bone loss in postmenopausal women. Lancet (1987) 2.76
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res (1996) 2.61
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med (2005) 2.47
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab (1994) 2.39
Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab (1997) 2.04
Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas (2004) 2.03
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol (2002) 2.03
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res (2003) 1.96
Paget disease of bone. J Clin Invest (2005) 1.92
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone (1996) 1.80
Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev (2005) 1.80
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest (1993) 1.78
Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. J Bone Miner Res (1995) 1.77
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res (2004) 1.76
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab (2001) 1.70
The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab (2004) 1.69
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res (2005) 1.68
The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab (1997) 1.66
Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med (1997) 1.63
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res (2005) 1.57
Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women. Osteoporos Int (1994) 1.57
Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med (1997) 1.54
Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am J Respir Crit Care Med (1995) 1.51
Differences in serum bone GLA protein with age and sex. Lancet (1984) 1.49
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res (1998) 1.32
Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab (1991) 1.30
The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med (1989) 1.28
Relationship of bone turnover to bone density and fractures. J Bone Miner Res (1997) 1.26
Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab (2004) 1.25
Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J Bone Miner Res (2001) 1.23
Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res (2004) 1.22
Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest (1988) 1.22
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int (2001) 1.20
Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. Am J Med (1990) 1.20
Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res (1990) 1.19
Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis (1996) 1.18
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res (2003) 1.17
Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J (2003) 1.17
Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res (2004) 1.16
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res (2005) 1.16
Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol (2006) 1.15
Increased bone resorption in moderate smokers with low body weight: the Minos study. J Clin Endocrinol Metab (2002) 1.11
Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol (1997) 1.11
Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone (1987) 1.09
Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res (1994) 1.09
Changes in bone turnover induced by aerobic and anaerobic exercise in young males. J Bone Miner Res (1998) 1.06
Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. J Clin Endocrinol Metab (1997) 1.06
Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ (1996) 1.05
Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res (2004) 1.05
Effects of low-dose prednisone on bone metabolism. J Bone Miner Res (2004) 1.05
Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab (1995) 1.04
Serum parathyroid hormone predicts time to fall independent of vitamin D status in a frail elderly population. J Clin Endocrinol Metab (2004) 1.03
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone (2004) 1.03
High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Miner Res (2006) 1.03
Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res (2004) 1.03
Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause (2004) 1.01
Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res (1997) 1.00
Vitamin K counteracts the effect of warfarin in liver but not in bone. Thromb Res (1987) 0.99
Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab (2005) 0.99
Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab (1994) 0.98
Effect of age-related chronic immobility on markers of bone turnover. J Bone Miner Res (2005) 0.96
Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int (1996) 0.96
Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporos Int (1990) 0.95
Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab (2005) 0.95
Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab (2003) 0.95
Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol (2005) 0.94
Markers of bone resorption in patients treated with pamidronate. Eur J Cancer (1998) 0.94
Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcif Tissue Int (1996) 0.93
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone (2004) 0.93
An open, crossover trial of calcium-fortified milk in prevention of early postmenopausal bone loss. Med J Aust (2001) 0.93
Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res (2005) 0.93
Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab (1992) 0.92
Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab (1995) 0.92
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res (2003) 0.90
The Tromsø Study: a population-based study on the variation in bone formation markers with age, gender, anthropometry and season in both men and women. Osteoporos Int (2001) 0.90
Impairment of bone turnover in elderly women with hip fracture. Calcif Tissue Int (1993) 0.90
Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int (2004) 0.90
Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann Rheum Dis (1992) 0.90
Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res (1993) 0.90
Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women. Maturitas (2001) 0.90
Prevention of hip fractures by correcting calcium and vitamin D insufficiencies in elderly people. Scand J Rheumatol Suppl (1996) 0.89
Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res (1995) 0.88
Bone density change and biochemical indices of skeletal turnover. Calcif Tissue Int (1996) 0.88
Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int (1999) 0.87